Boceprevir (Victrelis) for HCV: V is for victory and very complex
Michael Charlton, Michael D. Leise – 28 October 2011
The long and the short of interferon‐gamma–inducible protein 10 in hepatitis C virus infection
Mark D. Gorrell, Amany Zekry, Geoffrey W. McCaughan, Andrew Lloyd – 28 October 2011
Efficient human fetal liver cell isolation protocol based on vascular perfusion for liver cell–based therapy and case report on cell transplantation
Bruno Gridelli, Giovanni Vizzini, Giada Pietrosi, Angelo Luca, Marco Spada, Salvatore Gruttadauria, Davide Cintorino, Giandomenico Amico, Cinzia Chinnici, Toshio Miki, Eva Schmelzer, Pier Giulio Conaldi, Fabio Triolo, Jörg C. Gerlach – 27 October 2011 – Although hepatic cell transplantation (CT) holds the promise of bridging patients with end‐stage chronic liver failure to whole liver transplantation, suitable cell populations are under debate.
Of mice and men, calcineurin inhibitors and hepatitis C
Alleluiah Rutebemberwa, Hugo R. Rosen – 27 October 2011
Rifaximin reduces endotoxemia and improves liver function and disease severity in patients with decompensated cirrhosis
Georgios N. Kalambokis, Epameinondas V. Tsianos – 26 October 2011
Claudin‐1 involved in neonatal ichthyosis sclerosing cholangitis syndrome regulates hepatic paracellular permeability
Brigitte Grosse, Doris Cassio, Nadya Yousef, Céline Bernardo, Emmanuel Jacquemin, Emmanuel Gonzales – 26 October 2011 – Neonatal ichthyosis and sclerosing cholangitis (NISCH) syndrome is a liver disease caused by mutations of CLDN1 encoding Claudin‐1, a tight‐junction (TJ) protein. In this syndrome, it is speculated that cholestasis is caused by Claudin‐1 absence, leading to increased paracellular permeability and liver injuries secondary to paracellular bile regurgitation. We studied the role of claudin‐1 in hepatic paracellular permeability.
Preoperative fasting protects mice against hepatic ischemia/reperfusion injury: Mechanisms and Effects on liver regeneration
Ricky Harminder Bhogal, Barnaby Thomas Francis Stephenson, Simon Charles Afford – 26 October 2011
Quantitative liver function tests improve the prediction of clinical outcomes in chronic hepatitis C: Results from the hepatitis C antiviral long‐term treatment against cirrhosis trial
Gregory T. Everson, Mitchell L. Shiffman, John C. Hoefs, Timothy R. Morgan, Richard K. Sterling, David A. Wagner, Shannon Lauriski, Teresa M. Curto, Anne Stoddard, Elizabeth C. Wright, the HALT‐C Trial Group – 26 October 2011 – Risk for future clinical outcomes is proportional to the severity of liver disease in patients with chronic hepatitis C virus (HCV). We measured disease severity by quantitative liver function tests (QLFTs) to determine cutoffs for QLFTs that identified patients who were at low and high risk for a clinical outcome.
Plasma cells and the chronic nonsuppurative destructive cholangitis of primary biliary cirrhosis
Toru Takahashi, Tomofumi Miura, Junichiro Nakamura, Satoshi Yamada, Tsutomu Miura, Masahiko Yanagi, Yasunobu Matsuda, Hiroyuki Usuda, Iwao Emura, Koichi Tsuneyama, Xiao‐Song He, M. Eric Gershwin – 26 October 2011 – There has been increased interest in the role of B cells in the pathogenesis of primary biliary cirrhosis (PBC). Although the vast majority of patients with this disease have anti‐mitochondrial antibodies, there is no correlation of anti‐mitochondrial antibody titer and/or presence with disease severity.
Addition of simvastatin to cold storage solution prevents endothelial dysfunction in explanted rat livers
Lucia Russo, Jorge Gracia‐Sancho, Héctor García‐Calderó, Giusi Marrone, Juan Carlos García‐Pagán, Guillermo García‐Cardeña, Jaime Bosch – 26 October 2011 – Pathophysiological alterations in the endothelial phenotype result in endothelial dysfunction. Flow cessation, occurring during organ procurement for transplantation, triggers the endothelial dysfunction characteristic of ischemia/reperfusion injury, partly due to a reduction in the expression of the vasoprotective transcription factor Kruppel‐like Factor 2 (KLF2).